Janus Henderson Group PLC Raises Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

Janus Henderson Group PLC increased its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 5.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,159,888 shares of the company's stock after purchasing an additional 203,010 shares during the quarter. Janus Henderson Group PLC owned approximately 7.26% of Structure Therapeutics worth $112,816,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Ensign Peak Advisors Inc grew its stake in Structure Therapeutics by 67.7% in the fourth quarter. Ensign Peak Advisors Inc now owns 308,241 shares of the company's stock worth $8,359,000 after purchasing an additional 124,456 shares in the last quarter. DAFNA Capital Management LLC grew its stake in Structure Therapeutics by 4.4% in the fourth quarter. DAFNA Capital Management LLC now owns 35,500 shares of the company's stock worth $963,000 after purchasing an additional 1,500 shares in the last quarter. Deep Track Capital LP grew its stake in Structure Therapeutics by 129.4% in the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock worth $75,936,000 after purchasing an additional 1,579,492 shares in the last quarter. Baker BROS. Advisors LP boosted its position in Structure Therapeutics by 322.9% during the 4th quarter. Baker BROS. Advisors LP now owns 361,565 shares of the company's stock valued at $9,806,000 after acquiring an additional 276,065 shares in the last quarter. Finally, BNP Paribas Financial Markets bought a new stake in Structure Therapeutics during the 4th quarter valued at $304,000. Institutional investors own 91.78% of the company's stock.

Structure Therapeutics Trading Up 3.0%

Shares of GPCR traded up $0.74 during midday trading on Friday, hitting $25.17. 826,116 shares of the company's stock traded hands, compared to its average volume of 934,882. Structure Therapeutics Inc. has a 1 year low of $13.22 and a 1 year high of $62.74. The firm's fifty day moving average is $21.19 and its 200-day moving average is $26.37. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -34.01 and a beta of -1.69.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). On average, equities research analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on GPCR. Citigroup began coverage on Structure Therapeutics in a research report on Friday, May 2nd. They set a "buy" rating and a $60.00 target price on the stock. William Blair began coverage on Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating on the stock. Finally, HC Wainwright dropped their target price on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research report on Monday, May 12th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics has an average rating of "Buy" and a consensus target price of $78.00.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.